Accuray Receives 510(k) Clearance for a Rotational Dose Control for the TomoTherapy System

SUNNYVALE, Calif. — October 25, 2011 — Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market the Dose Control System (DCS), a new feature for Accuray’s TomoTherapy® System that improves system performance.

The TomoTherapy System revolutionized radiation therapy with the introduction of helical delivery, providing precise application of dose to target structures while sparing healthy tissue. With the advent of the Dose Control System the TomoTherapy System again breaks new ground as the first dose servo-controlled helical delivery system (patent pending). This approach provides even higher precision with unprecedented dose stability throughout complex rotational treatments. Static delivery provided by the TomoDirectTM option also benefits from a more stable and consistent dose rate at every gantry angle.

The new DCS feature provides these gains by automatically adjusting controls previously handled through a manual process. This means small variations in dose rate are immediately corrected by the system, resulting in fewer interruptions. The DCS application also ensures a more stable output over longer duration treatments, such as Total Marrow and Total Body Irradiation. The result of this new product feature is higher customer satisfaction, a better patient experience, and improved overall system performance.

source: Accuray